Koselugo (Selumetinib) Capsule
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Koselugo (Selumetinib) Capsule contains selumetinib, a MEK inhibitor. Its labelling describes it as a treatment for children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas — benign tumours that grow along nerves — described as slowing tumour growth and reducing tumour size.
Product Information
The following description reflects information associated with selumetinib and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for paediatric patients (2 years and older) with neurofibromatosis type 1 (NF1)
- Described for symptomatic, inoperable plexiform neurofibromas
- Described as slowing tumour growth, reducing tumour volume and easing related symptoms
Described Dosage & Administration
- Taken by mouth, with or without food, at the same times each day as prescribed
- Capsules are swallowed whole — not opened, chewed or dissolved
- Grapefruit and grapefruit juice are described as needing to be avoided during treatment
- Exact dose is set by the treating specialist based on body surface area
Described Side Effects
Commonly described side effects include:
- Nausea, vomiting and diarrhoea
- Abdominal pain
- Rash, dry skin or itching
- Fever
- Fatigue
- Bone, muscle or joint pain
- Headache
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Heart or liver problems should be disclosed; cardiac and eye monitoring is described in the labelling
- New visual disturbance, chest symptoms or swelling should be reported promptly
- Grapefruit and certain interacting medicines should be avoided
- Pregnancy or breastfeeding should be discussed with the prescriber
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains selumetinib and is described for children aged 2 and older with NF1-related symptomatic, inoperable plexiform neurofibromas. SDO Pharma has not independently verified these claims.
Its labelling describes grapefruit as able to raise selumetinib levels in the body; the manufacturer’s prescribing information gives full dietary and interaction guidance.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.